Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancer.
Biomarkers, Tumor
/ genetics
Chromatography, Liquid
/ methods
Fixatives
/ chemistry
Formaldehyde
/ chemistry
Humans
Paraffin Embedding
/ methods
Proteins
/ analysis
Proteomics
/ methods
Specimen Handling
/ methods
Tandem Mass Spectrometry
/ methods
Tissue Fixation
/ methods
Tissue Preservation
/ methods
Urinary Bladder Neoplasms
/ diagnosis
Urologic Neoplasms
/ diagnosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 04 2021
07 04 2021
Historique:
received:
10
07
2020
accepted:
22
03
2021
entrez:
8
4
2021
pubmed:
9
4
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Samples in biobanks are generally preserved by formalin-fixation and paraffin-embedding (FFPE) and/or optimal cutting temperature compound (OCT)-embedding and subsequently frozen. Mass spectrometry (MS)-based analysis of these samples is now available via developed protocols, however, the differences in results with respect to preservation methods needs further investigation. Here we use bladder urothelial carcinoma tissue of two different tumor stages (Ta/T1-non-muscle invasive bladder cancer (NMIBC), and T2/T3-muscle invasive bladder cancer (MIBC)) which, upon sampling, were divided and preserved by FFPE and OCT. Samples were parallel processed from the two methods and proteins were analyzed with label-free quantitative MS. Over 700 and 1200 proteins were quantified in FFPE and OCT samples, respectively. Multivariate analysis indicates that the preservation method is the main source of variation, but also tumors of different stages could be differentiated. Proteins involved in mitochondrial function were overrepresented in OCT data but missing in the FFPE data, indicating that these proteins are not well preserved by FFPE. Concordant results for proteins such as HMGCS2 (uniquely quantified in Ta/T1 tumors), and LGALS1, ANXA5 and plastin (upregulated in T2/T3 tumors) were observed in both FFPE and OCT data, which supports the use of MS technology for biobank samples and encourages the further evaluation of these proteins as biomarkers.
Identifiants
pubmed: 33828141
doi: 10.1038/s41598-021-87003-6
pii: 10.1038/s41598-021-87003-6
pmc: PMC8027873
doi:
Substances chimiques
Biomarkers, Tumor
0
Fixatives
0
Proteins
0
Formaldehyde
1HG84L3525
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7595Références
Anal Chem. 2018 May 1;90(9):5841-5849
pubmed: 29624047
Nat Immunol. 2017 May;18(5):583-593
pubmed: 28263321
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Am J Pathol. 2019 Mar;189(3):619-631
pubmed: 30770125
Annu Rev Biomed Eng. 2009;11:49-79
pubmed: 19400705
Nucleic Acids Res. 2020 Jan 8;48(D1):D1145-D1152
pubmed: 31686107
Anal Biochem. 2014 Feb 1;446:76-81
pubmed: 24161613
Int J Cancer. 2020 Jan 1;146(1):281-294
pubmed: 31286493
Epigenetics. 2008 Mar-Apr;3(2):64-8
pubmed: 18437052
Methods Enzymol. 2017;585:15-27
pubmed: 28109427
Cancer Biol Ther. 2006 Aug;5(8):967-75
pubmed: 16775426
Methods. 2015 Jun 15;81:50-5
pubmed: 25721092
BJU Int. 2009 Dec;104(11):1780-5
pubmed: 19522865
Nat Genet. 2003 Jan;33(1):90-6
pubmed: 12469123
Mol Cancer Res. 2011 Dec;9(12):1573-86
pubmed: 21970856
Oncotarget. 2014 Jan 30;5(2):506-18
pubmed: 24504108
Can J Gastroenterol Hepatol. 2019 Jul 1;2019:8348967
pubmed: 31355161
J Pathol. 2017 May;242(1):113-125
pubmed: 28195647
Clin Proteomics. 2018 Aug 3;15:26
pubmed: 30087585
J Proteomics. 2017 Aug 23;166:59-67
pubmed: 28709933
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
Mol Carcinog. 2008 Sep;47(9):678-85
pubmed: 18288642
Clin Cancer Res. 2012 Jun 15;18(12):3377-86
pubmed: 22553347
Sci Signal. 2018 Jan 30;11(515):
pubmed: 29382783
EuPA Open Proteom. 2015 Nov 02;10:9-18
pubmed: 29900094
Cell Mol Life Sci. 2016 May;73(10):2105-21
pubmed: 26781467
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Pathology. 2012 Oct;44(6):506-12
pubmed: 22772342
Clin Chim Acta. 2014 Jan 1;427:42-8
pubmed: 24121031
Expert Opin Biol Ther. 2008 Jan;8(1):45-57
pubmed: 18081536
Oncol Rep. 2017 Sep;38(3):1605-1612
pubmed: 28731192
Pathol Res Pract. 2019 Aug;215(8):152464
pubmed: 31176575
J Proteome Res. 2011 Jul 1;10(7):3040-9
pubmed: 21526778
Genet Mol Res. 2013 May 06;12(2):1479-89
pubmed: 23765955
Methods Mol Biol. 2018;1711:133-148
pubmed: 29344888
Annu Rev Biochem. 2012;81:379-405
pubmed: 22439968
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Neoplasia. 2018 Sep;20(9):894-904
pubmed: 30121007
Proteomics. 2014 Mar;14(4-5):441-51
pubmed: 24339433
J Proteome Res. 2010 Jul 2;9(7):3688-700
pubmed: 20469934